Theralase Partners with Princess Margaret Cancer Centre
2014年5月15日 - 8:00PM
Access Wire
Toronto, Ontario / ACCESSWIRE / May 15, 2014 / Theralase Technologies Inc.
("Theralase') (TSXV: TLT)
(TLTFF: OTCBB) announced today that it has partnered
with Princess Margaret Cancer Centre, University Health Network
("UHN") to complete preclinical research on its Photo Dynamic
Compound (PDC) technology for the destruction of cancer.
Under the terms of the
agreement, Theralase's scientific and engineering teams will work
with UHN's scientific and medical cancer specialists to complete
preclinical research for the anti-cancer technology in the
destruction of cancer and to advance the technology to the clinical
stage. Anticipated 2014 milestones include the destruction of
bladder cancer in a rat model, verification of the lead PDC for
bladder cancer, validation of manufactured PDC quality and
toxicology analysis assistance.
Dr. Arkady Mandel, Chief
Scientific Officer of Theralase stated, "I am delighted that we
have partnered with UHN to complete this pivotal preclinical
research. UHN is one of the top five cancer centres in the world
and provides excellent clinical and scientific support to our
existing teams to complete the preclinical work required to prepare
us for a Phase 1/2a human clinical trial for bladder
cancer.
Dr. Lothar Lilge, PhD, Senior
Research Scientist at UHN stated, "The initial in-vitro and small
animal in-vivo work using Theralase's anti-cancer PDC technology
has been excellent, demonstrating elimination of a wide range of
cancer cells at sub micromolar concentations (nanograms of PDC)
when light activated and without toxicity in the absence of light.
Eliminating subcutaneous tumours in in vivo small animals with this
non-invasive and non-ionizing technology bodes very well for the
anticipated clinical destruction of cancer in the
future."
Dr. Michael Jewett MD,
clinician investigator and uro-oncologist at Princess Margaret/UHN
stated, "I am encouraged that Theralase has continued to pursue
investigating the possibility of destroying bladder cancer with
their anti-cancer PDC technology. Bladder cancer is a devastating
disease with over 386,000 new cases annually worldwide and no new
drug treatments approved since 1998. If, with the support of UHN,
Theralase is able to prove its safety and efficacy in clinical
trials, we have a game changer on our hands in the management and
treatment of patients with bladder cancer."
Roger Dumoulin-White,
President and CEO of Theralase stated that, "I am pleased that
Theralase has chosen a strong partner like UHN to help us complete
our preclinical research and help us to prepare for human clinical
trials. UHN will be strategic for Theralase to help complete our
preclinical work by early 2015 and allow us to commence human
clinical trials with them and a large US cancer facility soon
thereafter."
About Theralase Technologies
Inc.
Theralase Technologies Inc.
designs, manufactures and markets patented, superpulsed laser
technology used in eliminating pain and destroying cancer.
Theralase technology is safe and effective in eliminating pain,
reducing inflammation and accelerating tissue regeneration of
numerous nerve, muscle and joint conditions. Theralase is actively
developing patented technology that is able to target and destroy
cancers, bacteria and viruses when light activated.
Additional information is
available at www.theralase.com and
www.sedar.com .
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange
nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchanges) accepts responsibility
for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) x 225
416.699.LASE (5273) x 225
rwhite@theralase.com
www.theralase.com
Jane Finlayson
Senior Public Affairs Advisor
Princess Margaret Hospital, University Health
Network
416-946-2846
jane.finlayson@uhn.on.ca
www.uhn.ca
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
過去 株価チャート
から 5 2024 まで 6 2024
Theralase Technologies (TSXV:TLT)
過去 株価チャート
から 6 2023 まで 6 2024